Physician profile
Sam Safaee
NPI 1609172030
$2,271.15
in general payments reported to CMS, 2019-2025
21 companies · $654 in 2025
The $654 reported for 2025 was more than what 76% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $775 · 2022: $464 · 2023: $83.76 · 2024: $294 · 2025: $654.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,032.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,032.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $461.30 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $218.13 | 2021-2022 | |
| Alkermes, INC. | $175.16 | 2021-2025 | Aristada, Lybalvi |
| Lilly USA, LLC | $170.46 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $166.16 | 2021-2025 | Abilify Asimtufii, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $161.31 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $111.14 | 2025 | Gemtesa |
| Amgen INC. | $107.28 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $104.75 | 2024 | Inpefa |
| Lundbeck LLC | $94.51 | 2021-2025 | Abilify Asimtufii |
| Tris Pharma INC | $93.13 | 2025 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $89.05 | 2022-2025 | Qelbree |
| Teva Pharmaceuticals USA, INC. | $70.83 | 2023-2024 | Uzedy |
| Vanda Pharmaceuticals INC. | $67.35 | 2025 | Fanapt |
| Pfizer INC. | $52.38 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $30.56 | 2021 | |
| Indivior INC. | $26.61 | 2022 | |
| Almatica Pharma LLC | $21.06 | 2025 | Loreev Xr |
| Scilex Pharmaceuticals INC. | $19.31 | 2021 | |
| Neurocrine Biosciences, INC. | $16.30 | 2024 | Ingrezza |
| Arbor Pharmaceuticals, INC. | $14.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sam Safaee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.